ATE93143T1 - Verwendung eines lysozymdimeren und/oder ribonucleasedimeren zur herstellung eines antiviralen oder antibakteriellen arzneimittels. - Google Patents

Verwendung eines lysozymdimeren und/oder ribonucleasedimeren zur herstellung eines antiviralen oder antibakteriellen arzneimittels.

Info

Publication number
ATE93143T1
ATE93143T1 AT88905146T AT88905146T ATE93143T1 AT E93143 T1 ATE93143 T1 AT E93143T1 AT 88905146 T AT88905146 T AT 88905146T AT 88905146 T AT88905146 T AT 88905146T AT E93143 T1 ATE93143 T1 AT E93143T1
Authority
AT
Austria
Prior art keywords
dimer
antiviral
ribonuclease
lysozyme
manufacture
Prior art date
Application number
AT88905146T
Other languages
English (en)
Inventor
Witold Kiczka
Original Assignee
Nika Health Products Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nika Health Products Ltd filed Critical Nika Health Products Ltd
Application granted granted Critical
Publication of ATE93143T1 publication Critical patent/ATE93143T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/47Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
AT88905146T 1988-05-26 1988-05-26 Verwendung eines lysozymdimeren und/oder ribonucleasedimeren zur herstellung eines antiviralen oder antibakteriellen arzneimittels. ATE93143T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US17858888A 1988-05-26 1988-05-26
EP88905146A EP0380484B1 (de) 1988-05-26 1988-05-26 Verwendung eines Lysozymdimeren und/oder Ribonucleasedimeren zur Herstellung eines antiviralen oder antibakteriellen Arzneimittels
PCT/US1988/001785 WO1989011294A1 (en) 1988-05-26 1988-05-26 Antiviral or antibacterial compound and method of use
OA59731A OA09785A (en) 1988-05-26 1990-01-26 Antiviral or antibacterial compound and method of use

Publications (1)

Publication Number Publication Date
ATE93143T1 true ATE93143T1 (de) 1993-09-15

Family

ID=33162813

Family Applications (1)

Application Number Title Priority Date Filing Date
AT88905146T ATE93143T1 (de) 1988-05-26 1988-05-26 Verwendung eines lysozymdimeren und/oder ribonucleasedimeren zur herstellung eines antiviralen oder antibakteriellen arzneimittels.

Country Status (23)

Country Link
US (3) US5200182A (de)
EP (1) EP0380484B1 (de)
JP (1) JPH0649659B2 (de)
AT (1) ATE93143T1 (de)
AU (1) AU624331B2 (de)
BG (1) BG60544B1 (de)
CA (1) CA1335425C (de)
CS (1) CS277030B6 (de)
DK (1) DK173078B1 (de)
ES (1) ES2011577A6 (de)
FI (1) FI900412A7 (de)
HK (1) HK42394A (de)
HU (1) HU204710B (de)
IL (1) IL90092A (de)
LV (1) LV10054B (de)
MA (1) MA21560A1 (de)
MW (1) MW390A1 (de)
OA (1) OA09785A (de)
PH (1) PH26284A (de)
RU (1) RU2092183C1 (de)
WO (1) WO1989011294A1 (de)
YU (1) YU109289A (de)
ZA (1) ZA893382B (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0649659B2 (ja) * 1988-05-26 1994-06-29 ニカヘルス プロダクツ,リミテッド 抗ウイルス及び抗菌組成物並びに使用方法
US5989880A (en) 1990-01-08 1999-11-23 Nika Health Products Ltd. Method of preparing lysozyme dimers
BR9007970A (pt) * 1990-01-08 1992-11-17 Nika Health Products Ltd Processo para preparacao de dimeros de ribonuclease
PL173978B1 (pl) * 1992-07-13 1998-05-29 Nika Health Products Ltd Sposób oddziaływania na wydzielanie cytokin w hodowli limfocytów krwi obwodowej
CH682541A5 (de) * 1992-06-23 1993-10-15 Urs Viktor Dr Wirth Biochemische Inaktivierung von RNA-Viren.
US6183742B1 (en) 1992-07-13 2001-02-06 Nika Health Products, Limited Applications of lysozyme dimer
DZ1964A1 (fr) * 1995-01-13 2002-10-15 Nika Health Products Ltd Nouvelle applications d'un dimère de lysozyme.
GB2304048A (en) * 1995-08-12 1997-03-12 John William Carson Medicament containing saliva extract
US6123937A (en) * 1997-03-14 2000-09-26 Nika Health Products, Limited Applications of lysozyme dimer
RU2157206C1 (ru) * 1999-03-10 2000-10-10 Оренбургская государственная медицинская академия Бактерицидный отогель
RU2172179C2 (ru) * 1999-06-24 2001-08-20 Сельков Сергей Алексеевич Шарики "биосан" для лечения кольпитов различного генеза и способ лечения кольпитов различного генеза
RU2191576C2 (ru) * 1999-07-27 2002-10-27 Уральский научно-исследовательский институт дерматовенерологии и иммунопатологии Способ лечения субклинической формы генитальной герпесвирусной инфекции у женщин
RU2200550C2 (ru) * 1999-10-29 2003-03-20 Научно-исследовательская лаборатория иммунохимиотерапии лепры и иммунотропных средств с клиникой и опытно-экспериментальным производством Новые лекарственные формы димоцифона в терапии лепры, зудящих и аллергодерматозов, герпетиформного дерматита дюринга
RU2163119C1 (ru) * 2000-04-26 2001-02-20 Свистов Виталий Владимирович Антисептическое средство
RU2180593C1 (ru) * 2000-11-08 2002-03-20 Айламазян Эдуард Карпович Фармацевтическая композиция для лечения и профилактики генитального герпеса, хронической папилломы вирусной инфекции и профилактики рака шейки матки (варианты)
US6716813B2 (en) * 2000-11-28 2004-04-06 House Ear Institute Use of antimicrobial proteins and peptides for the treatment of otitis media and paranasal sinusitis
US7338936B2 (en) * 2000-11-28 2008-03-04 House Ear Institute Use of antimicrobial proteins and peptides for the treatment of otitis media and paranasal sinusitis
RU2177781C1 (ru) * 2000-12-06 2002-01-10 Научный Центр Здоровья детей РАМН Суппозитории ректальные, содержащие витаминный комплекс
JP2002187853A (ja) * 2000-12-21 2002-07-05 Shinei Ferumentekku:Kk 動物の乳頭除菌剤および菌環境改善方法
RU2195927C1 (ru) * 2001-07-13 2003-01-10 ООО "Тенториум" Абиес-свеча "канделла-два"
DE10210285A1 (de) * 2002-03-08 2003-11-13 Medigene Ag Reversibles Toxin und seine Verwendung
JP2008505853A (ja) 2004-04-13 2008-02-28 クインテセンス バイオサイエンシーズ インコーポレーティッド 細胞傷害性薬剤としての非天然のリボヌクレアーゼ複合体
US20050244402A1 (en) * 2004-04-30 2005-11-03 Villanueva Julie M Absorption of pain-causing agents
US7348301B2 (en) * 2006-02-16 2008-03-25 Buckman Laboratories International, Inc. Lysozyme-based method and composition to control the growth of microorganisms in aqueous systems
US8840882B2 (en) * 2006-06-23 2014-09-23 Quintessence Biosciences, Inc. Modified ribonucleases
WO2008010991A2 (en) 2006-07-17 2008-01-24 Quintessence Biosciences, Inc. Methods and compositions for the treatment of cancer
RU2009136424A (ru) * 2007-03-02 2011-04-10 СЕНТ СИМЕОН ЭлДиЭй (US) Композиция и способ лечения папилломавируса и саркоидов лошадей
US20100317677A1 (en) * 2007-09-11 2010-12-16 Hassel Bret A Methods of Treating a Microbial Infection by Modulating RNase-L Expression and/or Activity
WO2009048909A1 (en) * 2007-10-08 2009-04-16 Quintessence Biosciences, Inc. Compositions and methods for ribonuclease-based therapies
BRPI0920743A2 (pt) 2008-10-01 2016-09-20 Quintessence Biosciences Inc ribonucleases terapeuticas
US20100215707A1 (en) * 2009-02-25 2010-08-26 Mcdonald Thomas Activated creatinine and precursors thereof as antibacterial agents, compositions and products containing such agents and uses thereof
NZ600269A (en) 2009-05-20 2014-02-28 Dec Int Nz Ltd Delivery device for treatment of mastitis
EP2457576B1 (de) 2010-11-29 2020-07-08 Eurochit Danuta Kruszewska Lactobacillus reuteri Stamm zur Verwendung der medizinischen und tiermedizinischen Prophylaxe und Behandlung von dem metabolischen Syndrom oder Infektionen
RU2548803C2 (ru) * 2011-11-28 2015-04-20 Общество с ограниченной ответственностью " Фарматренд" ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ ДЛЯ ЛЕЧЕНИЯ ГЛАЗНЫХ ИНФЕКЦИЙ P. Aeruginosa, СОДЕРЖАЩАЯ РЕКОМБИНАНТНЫЙ ЛИЗОЦИМ
RU2509801C2 (ru) * 2012-03-22 2014-03-20 Борис Михайлович Куриненко СПОСОБ ИСПОЛЬЗОВАНИЯ РИБОНУКЛЕАЗЫ Bacillus intermedius
EP2674162A1 (de) 2012-05-29 2013-12-18 Danuta Kruszewska Nanoprodukt, beinhaltend lactobacillus reuteri dan080, zur verwendung bei der prophylaxe, diagnose sowie bei der medizinischen and veterinärmedizinischen behandlung
CN104684565A (zh) 2012-05-29 2015-06-03 达努塔·克鲁谢夫斯卡 在人类和兽医的预防和医疗中有用的、包含罗伊氏乳杆菌dan080的纳米产品及其医疗用途
RU2504397C1 (ru) * 2012-10-25 2014-01-20 Леонид Леонидович Клопотенко Фармацевтическая композиция, содержащая фермент рибонуклеазу и глицирризиновую кислоту или ее соли: глицирризинат аммония, или дикалия, или тринатрия
WO2014152678A1 (en) 2013-03-15 2014-09-25 University Of Massachusetts Compositions and methods for delivering agents to the central nervous system
US9573980B2 (en) 2013-03-15 2017-02-21 Spogen Biotech Inc. Fusion proteins and methods for stimulating plant growth, protecting plants from pathogens, and immobilizing Bacillus spores on plant roots
EP3108894B1 (de) 2014-02-21 2022-01-26 Kewpie Corporation Nicht-therapeutisches verfahren zur inaktivierung von norovirus, verwendung einer lysozymkomponente zur nicht-therapeutischen norovirus-inaktivierung, und lysozymkomponente zur verwendung bei der prophylaxe oder therapie von norovirusinfektion
EP3175713A4 (de) * 2014-07-31 2018-04-18 Kewpie Corporation Wasserhaltige flüssige zusammensetzung, herstellungsverfahren dafür, verarbeitetes lysozym und/oder salz davon und verfahren zur herstellung davon
IL315468A (en) 2014-09-17 2024-11-01 Spogen Biotech Inc Fusion proteins, recombinant bacteria, and methods for using recombinant bacteria
LV15071B (lv) * 2015-07-14 2016-02-20 Rīgas Stradiņa Universitāte Kompozīcija subklīniska mastīta ārstēšanai govīm
RU2634264C1 (ru) * 2016-09-19 2017-10-24 Александр Ливиевич Ураков Крем-молочко для лечения опоясывающего лишая
CN110088650B (zh) 2016-12-28 2021-09-07 Dic株式会社 分散体和使用其的喷墨用油墨组合物、光转换层、和液晶显示元件
AR113123A1 (es) 2017-09-20 2020-01-29 Spogen Biotech Inc Proteínas de fusión, bacterias recombinantes y fragmentos del exosporio para promover la salud de las plantas
WO2021021765A1 (en) * 2019-07-26 2021-02-04 Evolve Biosystems, Inc. Nutritive compositions with bioactive proteins

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1268M (fr) * 1961-06-29 1962-04-24 Puiseux Médicament antimitotique et antiviral.
FR4020M (de) * 1965-01-29 1966-03-21
DE1517751C3 (de) * 1965-07-08 1975-02-27 Eisai Co., Ltd., Tokio Verfahren zum Verhindern der Bildung von flockigen Lysozym- und/oder Lysozymsalzniederschlägen in wässrigen Lösungen, die Lysozym und/oder Lysozymsalze enthalten
DE1545644A1 (de) * 1965-12-06 1969-08-07 Boehringer Sohn Ingelheim Verfahren zur Herstellung von neuen quaternaeren Scopolammoniumsalzen
GB1110504A (en) * 1966-03-18 1968-04-18 Prodotti Antibiotici Spa Pharmaceutical compositions
US4221794A (en) * 1979-06-21 1980-09-09 Newport Pharmaceuticals International, Inc. Method of imparting immunomodulating and antiviral activity
US4510144A (en) * 1981-08-26 1985-04-09 Newport Pharmaceuticals International Methods of imparting immunomodulating activity with dihydrothiazolo purine derivatives
CA1263378A (en) * 1985-01-08 1989-11-28 Robert James Alaimo Imidazo¬4,5-f|quinolines useful as immunomodulating agents
US4739046A (en) * 1985-08-19 1988-04-19 Luzio Nicholas R Di Soluble phosphorylated glucan
US4744984A (en) * 1985-10-08 1988-05-17 Vetrepharm Research, Inc. Antiviral immunotherapeutic agent and preparation thereof
JPH0649659B2 (ja) * 1988-05-26 1994-06-29 ニカヘルス プロダクツ,リミテッド 抗ウイルス及び抗菌組成物並びに使用方法

Also Published As

Publication number Publication date
US6099835A (en) 2000-08-08
HK42394A (en) 1994-05-13
DK16890A (da) 1990-01-22
HUT54060A (en) 1991-01-28
FI900412A0 (fi) 1990-01-25
WO1989011294A1 (en) 1989-11-30
CS277030B6 (en) 1992-11-18
IL90092A (en) 1995-03-30
HU883981D0 (en) 1990-12-28
AU1940888A (en) 1989-12-12
EP0380484A1 (de) 1990-08-08
ZA893382B (en) 1991-01-30
MW390A1 (en) 1990-11-14
CS318089A3 (en) 1992-05-13
BG91270A (bg) 1993-12-24
BG60544B1 (en) 1995-08-28
EP0380484B1 (de) 1993-08-18
CA1335425C (en) 1995-05-02
HU204710B (en) 1992-02-28
PH26284A (en) 1992-04-10
YU109289A (en) 1991-08-31
MA21560A1 (fr) 1989-12-31
JPH03504121A (ja) 1991-09-12
AU624331B2 (en) 1992-06-11
OA09785A (en) 1994-04-15
ES2011577A6 (es) 1990-01-16
LV10054B (en) 1995-02-20
DK173078B1 (da) 1999-12-20
JPH0649659B2 (ja) 1994-06-29
LV10054A (lv) 1994-05-10
FI900412A7 (fi) 1990-01-25
DK16890D0 (da) 1990-01-22
RU2092183C1 (ru) 1997-10-10
US5466449A (en) 1995-11-14
US5200182A (en) 1993-04-06

Similar Documents

Publication Publication Date Title
ATE93143T1 (de) Verwendung eines lysozymdimeren und/oder ribonucleasedimeren zur herstellung eines antiviralen oder antibakteriellen arzneimittels.
ATE73331T1 (de) Verwendung von tetrahydrobiopterinen zur herstellung eines medikaments zur behandlung von kinderautismus.
DE69434963D1 (de) Selektiv auf die leber wirkende pharmazeutisch aktive substanz
DE69333321D1 (de) Verwendung eines Consensus-Interferons zur Reduzierung der Nebeneffekte in der Interferon Behandlung von viralen Hepatiten.
DE69636343D1 (de) Verwendung von glu-trp dipeptiden zur herstellung eines arzneimittels zur behandlung von verschiedenen gefässneubildung-assozierten erkrankungen
ES2160643T3 (es) Composiciones que contienen g-csf y proteina de union al tnf.
DE69535081D1 (de) Verwendung von Prostaglandin A oder dessen Derivaten zur Behandlung von Psoriasis
NO172043C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive n-2,3-butadienyl-triamioalkanderivater
ATE161725T1 (de) Verwendung von phosphatdiestern zur behandlung von erkrankungen der retina
ATE174798T1 (de) Die herstellung von zusammensetzungen zur behandlung von krankheiten der zellproliferation
AU2840889A (en) Method of treating haematologic diseases and pharmaceutical compositions to be used therefor
ATE316379T1 (de) Oxyhuminsäure und ihre verwendung zur behandlung von verschiedenenen störungen
DK0410749T3 (da) Anthocyanidiner til behandling af ophthalmiske sygdomme
ATE311897T1 (de) Behandlung von multiplersklerose mit einer kombination von interferon und wachstumshormone
MY106984A (en) Antiviral or antibacterial composition and method of use.
GEP19971029B (en) Antiviral or antibacterial compound and method of use thereof
GR1001006B (el) Μεθοδος παρασκευης και χρησιμοποιησεως αντιιικων η αντιβακτηριακων συνθεσεων.
DE68924316D1 (de) Menschliches Gamma-Interferon, Verfahren zu seiner Herstellung und seine Verwendung.
ATE56360T1 (de) Zusammensetzung zur herstellung eines arzneimittels zur therapeutischen behandlung von hauttrauma.
SE9003140D0 (sv) Method and composition for treatment of heart diseases

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time